In the BioHarmony Drug Report Database
Teprotumumab
Tepezza (teprotumumab) is an antibody pharmaceutical. Teprotumumab was first approved as Tepezza on 2020-01-21. It is used to treat graves ophthalmopathy in the USA. The pharmaceutical is active against insulin-like growth factor 1 receptor.
Trade Name
|
Tepezza |
|---|---|
Common Name
|
teprotumumab |
ChEMBL ID
|
CHEMBL1743079 |
Indication
|
graves ophthalmopathy |
Drug Class
|
Monoclonal antibodies |
Image (chem structure or protein)
